Q-omics provides the consensus-scored SLC12A8 profile across patient tissues and cancer cell-line models. SLC12A8 expression is associated with patient survival in 31 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SLC12A8 is differentially expressed in 17, with the highest sampling consensus in BLCA. Additionally, SLC12A8 RNA expression shows 19,125 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, BLCA, and LUAD as cancer lineages where SLC12A8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC12A8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC12A8 survival associations across molecular data types. SLC12A8 RNA expression shows survival associations in the most cancer types (31), followed by mutation status (1) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC12A8 RNA expression–survival associations across cancer types. High SLC12A8 expression shows unfavorable associations in KIRC, ACC, UVM, MESO, BLCA and KIRP. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SLC12A8 RNA expression.
This table summarizes SLC12A8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SLC12A8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC12A8 shows higher tumor expression in BLCA, COAD, HNSC, STAD, LUSC and LUAD. The BLCA box plot shows higher SLC12A8 RNA expression in tumor versus normal tissue (log2 FC = +2.632, t-test p < 0.001).
This table shows molecular features associated with SLC12A8 in patient tissues and cancer cell lines. In patient samples, SLC12A8 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC12A8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
